Literature DB >> 34351275

Risk of motor vehicle collisions after methadone use.

Ya-Hui Yang1, Pei-Shan Ho2,3, Trong-Neng Wu4, Peng-Wei Wang5, Chun-Hung Richard Lin6, Jui-Hsiu Tsai7,8,9, Yue Leon Guo8,10, Hung-Yi Chuang8,11,12.   

Abstract

Methadone maintenance treatment (MMT) can alleviate opioid dependence. However, MMT possibly increases the risk of motor vehicle collisions. The current study investigated preliminary estimation of motor vehicle collision incidence rates. Furthermore, in this population-based retrospective cohort study with frequency-matched controls, opiate adults receiving MMT (cases) and those not receiving MMT (controls) were identified at a 1:2 ratio by linking data from several nationwide administrative registry databases. From 2009 to 2016, the crude incidence rate of motor vehicle collisions was the lowest in the general adult population, followed by that in opiate adults, and it was the highest in adults receiving MMT. The incidence rates of motor vehicle collisions were significantly higher in opiate users receiving MMT than in those not receiving MMT. Kaplan-Meier curves of the incidence of motor vehicle collisions differed significantly between groups, with a significant increased risk during the first 90 days of follow-up. In conclusion, drivers receiving MMT have higher motor vehicle collision risk than those not receiving MMT in opiate users, and it is worthy of noticing road safety in such drivers, particularly during the first 90 days of MMT.
© 2021, Yang et al.

Entities:  

Keywords:  cohort study; human; medicine; methadone maintenance treatment; vehicle motor collision

Year:  2021        PMID: 34351275     DOI: 10.7554/eLife.63954

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  1 in total

1.  Incidence and Risk of Fatal Vehicle Crashes Among Professional Drivers: A Population-Based Study in Taiwan.

Authors:  Jui-Hsiu Tsai; Ya-Hui Yang; Pei-Shan Ho; Trong-Neng Wu; Yue Leon Guo; Pau-Chung Chen; Hung-Yi Chuang
Journal:  Front Public Health       Date:  2022-03-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.